Apr 18, 2023 / 07:00PM GMT
Gil Blum - Needham & Company - Analyst
Good afternoon, everyone, and thank you for joining us at the second day of the Needham and Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Co., and I cover both the gene therapy and immuno-oncology subsectors. It is my pleasure to have with me today, Geoff McDonough, the CEO of Generation Bio. (Conference Instructions)
Questions and Answers:
Gil Blum - Needham & Company - AnalystWithout further ado, we can get started. Some people don't know the Generation Bio story too well. Maybe as an introduction, just talk a little bit about the technology. And what is the problem that you're really trying to solve?
Geoff McDonough - Generation Bio Co. - President & Chief Executive Officer
Thanks, Gil, and thanks for the invitation to be here. It's always fun to chat and [it'd] be a great half an hour together.
Generation Bio is about redosable DNA therapeutics at scale and let's just parse what that